Bellevue Group AG Has $32.21 Million Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Bellevue Group AG reduced its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 0.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,460,693 shares of the biopharmaceutical company’s stock after selling 4,000 shares during the period. Bellevue Group AG owned about 7.29% of Sage Therapeutics worth $32,206,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Sage Therapeutics by 8.1% during the first quarter. Vanguard Group Inc. now owns 5,751,373 shares of the biopharmaceutical company’s stock worth $107,781,000 after purchasing an additional 432,013 shares during the period. Lazard Asset Management LLC acquired a new stake in Sage Therapeutics in the 1st quarter valued at $127,000. Price T Rowe Associates Inc. MD grew its position in Sage Therapeutics by 69.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company’s stock valued at $15,217,000 after acquiring an additional 333,805 shares during the period. Virtu Financial LLC acquired a new position in Sage Therapeutics during the first quarter worth $187,000. Finally, Harbor Capital Advisors Inc. lifted its holdings in shares of Sage Therapeutics by 43.6% during the second quarter. Harbor Capital Advisors Inc. now owns 37,572 shares of the biopharmaceutical company’s stock valued at $408,000 after acquiring an additional 11,409 shares during the period. Institutional investors own 99.22% of the company’s stock.

Wall Street Analysts Forecast Growth

SAGE has been the topic of several analyst reports. Truist Financial lowered their target price on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday, October 30th. Raymond James reiterated a “market perform” rating on shares of Sage Therapeutics in a research note on Thursday, October 10th. StockNews.com cut Sage Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. Oppenheimer cut their price objective on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Wednesday, October 30th. Finally, HC Wainwright restated a “neutral” rating and issued a $14.00 target price on shares of Sage Therapeutics in a research note on Wednesday, November 20th. Three equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $12.83.

Sage Therapeutics Stock Performance

NASDAQ:SAGE opened at $5.47 on Friday. Sage Therapeutics, Inc. has a 12-month low of $4.62 and a 12-month high of $28.26. The stock’s fifty day simple moving average is $6.49 and its 200-day simple moving average is $8.79.

Sage Therapeutics (NASDAQ:SAGE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing the consensus estimate of ($1.52) by ($0.01). The company had revenue of $11.87 million during the quarter, compared to analyst estimates of $10.80 million. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The company’s quarterly revenue was up 337.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($2.81) EPS. On average, equities analysts anticipate that Sage Therapeutics, Inc. will post -6.53 EPS for the current fiscal year.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.